Triglyceride-glucose index as a prognostic indicator in advanced gastric cancer: Insights and future research

Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment str...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 31; no. 17; p. 104794
Main Authors Zhao, Cheng-Fei, Liu, Xiao-Ling, Wu, Ning-Bi, Xu, Zhi-Feng
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 07.05.2025
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - blood
Blood Glucose - analysis
Humans
Immunotherapy - methods
Neoplasm Staging
Precision Medicine - methods
Prognosis
Progression-Free Survival
Stomach Neoplasms - blood
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - therapy
Treatment Outcome
Triglycerides - blood
Triglyceride-glucose index
Insulin resistance
Advanced gastric cancer
Prognostic indicator
Immunotherapy
Online AccessGet full text

Cover

Abstract Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao et al explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
AbstractList Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao et al explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao et al explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao et al explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao et al explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
Author Liu, Xiao-Ling
Zhao, Cheng-Fei
Wu, Ning-Bi
Xu, Zhi-Feng
Author_xml – sequence: 1
  givenname: Cheng-Fei
  surname: Zhao
  fullname: Zhao, Cheng-Fei
– sequence: 2
  givenname: Xiao-Ling
  surname: Liu
  fullname: Liu, Xiao-Ling
– sequence: 3
  givenname: Ning-Bi
  surname: Wu
  fullname: Wu, Ning-Bi
– sequence: 4
  givenname: Zhi-Feng
  surname: Xu
  fullname: Xu, Zhi-Feng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40521254$$D View this record in MEDLINE/PubMed
BookMark eNpVkctqGzEUhkVJqC_tC3QRtMxmHN3GmummhNAmhkA27lrI0tFYYSy50oxTv31lnIRmdW7_-Q-cb4YuQgyA0DdKFlyK5ubluVscOF14KheUCNmKT2jKGG0r1ghygaaUEFm1nMkJmuX8TAjjvGaf0USQmlFWiynarZPv-qOB5C1UXT-amAH7YOEv1hlrvE-xCzEP3py63ughppJhbQ86GLC403lIZWpOZfqOVyH7bjuU3WCxG4cxAU6QQSez_YIune4zfH2Nc_T718_13UP1-HS_urt9rAyvl0O1MdxwIV0rhLVEGMuAyKXkgupSSenMxpGmdabhTW0FhWXZsFy7pWSOAudz9OPsux83O7AGwpB0r_bJ73Q6qqi9-jgJfqu6eFCU0bptG1Icrl8dUvwzQh7UzmcDfa8DxDErXt5MSMvqukiv_j_2fuXtyUXAzgKTYs4J3LuEEnUiqQpJVUiqQlKdSfJ_fTyVLQ
Cites_doi 10.1038/s41571-023-00747-0
10.3390/curroncol31020075
10.1007/s13205-024-04202-4
10.1007/s10120-021-01222-4
10.1186/s12943-023-01827-6
10.1155/2015/508409
10.1016/j.ejim.2024.08.026
10.1161/CIRCULATIONAHA.111.090134
10.1055/s-2001-15494
10.1002/cam4.6837
10.1186/s40170-024-00332-8
10.7150/ijbs.70691
10.3390/ijms222011137
10.3389/fimmu.2024.1507283
10.1002/jcb.26174
10.1056/NEJMoa1500596
10.3389/fnut.2024.1515918
10.26574/maedica.2021.16.3.375
10.1056/NEJMoa2200075
10.1186/s12885-025-13816-7
10.3748/wjg.v31.i5.102249
10.3390/cancers17010154
10.5009/gnl17556
10.1136/jitc-2021-003091
ContentType Journal Article
Copyright The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. 2025
Copyright_xml – notice: The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
– notice: The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v31.i17.104794
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Zhao CF et al. Triglyceride-glucose index
EISSN 2219-2840
ExternalDocumentID PMC12159980
40521254
10_3748_wjg_v31_i17_104794
Genre Editorial
Commentary
GroupedDBID ---
123
29R
2WC
36B
53G
5VR
8WL
AAKDD
AAYXX
ACGFO
AENEX
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CITATION
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
HYE
OK1
P2P
RNS
RPM
TR2
XSB
CGR
CUY
CVF
ECM
EIF
FA0
NPM
7X8
5PM
ID FETCH-LOGICAL-c356t-bc3c347f944dd04cd2e0767341a04c77fcbf089fc8385d41e6bc3d3af672f1e33
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 18:26:20 EDT 2025
Fri Jul 11 17:05:32 EDT 2025
Sun Jun 29 01:31:22 EDT 2025
Sun Jul 06 05:06:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 17
Keywords Triglyceride-glucose index
Insulin resistance
Advanced gastric cancer
Prognostic indicator
Immunotherapy
Language English
License The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c356t-bc3c347f944dd04cd2e0767341a04c77fcbf089fc8385d41e6bc3d3af672f1e33
Notes SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
Author contributions: Zhao CF and Xu ZF designed this paper; Zhao CF and Liu XL wrote the paper; Zhao CF, Liu XL, Wu NB, and Xu ZF checked and proofread the paper, and searched related literature and information for this paper; all the authors have read and approved the final manuscript.
Supported by the Natural Science Foundation of Fujian Province, No. 2023J01160; Scientific Research Project of Putian University, No. 2022059; and Special Project for Outstanding Young Talents of Putian University, No. 2024072.
Corresponding author: Zhi-Feng Xu, Chief Physician, Department of Cardiothoracic Surgery, Affiliated Hospital of Putian University, No. 999 Dongzhen Road, Licheng District, Putian 351100, Fujian Province, China. zhifengxu1972@163.com
Co-first authors: Cheng-Fei Zhao and Xiao-Ling Liu.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC12159980
PMID 40521254
PQID 3219009255
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_12159980
proquest_miscellaneous_3219009255
pubmed_primary_40521254
crossref_primary_10_3748_wjg_v31_i17_104794
PublicationCentury 2000
PublicationDate 2025-5-7
2025-May-07
20250507
PublicationDateYYYYMMDD 2025-05-07
PublicationDate_xml – month: 05
  year: 2025
  text: 2025-5-7
  day: 07
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World J Gastroenterol
PublicationYear 2025
Publisher Baishideng Publishing Group Inc
Publisher_xml – name: Baishideng Publishing Group Inc
References B20
B10
B21
B11
B22
B12
B23
B13
B24
B14
B15
B16
B17
B18
B19
B1
B2
B3
B4
B5
B6
B7
B8
B9
References_xml – ident: B1
  doi: 10.1038/s41571-023-00747-0
– ident: B7
  doi: 10.3390/curroncol31020075
– ident: B17
  doi: 10.1007/s13205-024-04202-4
– ident: B9
  doi: 10.1007/s10120-021-01222-4
– ident: B14
  doi: 10.1186/s12943-023-01827-6
– ident: B18
  doi: 10.1155/2015/508409
– ident: B4
  doi: 10.1016/j.ejim.2024.08.026
– ident: B16
  doi: 10.1161/CIRCULATIONAHA.111.090134
– ident: B3
  doi: 10.1055/s-2001-15494
– ident: B11
  doi: 10.1002/cam4.6837
– ident: B13
  doi: 10.1186/s40170-024-00332-8
– ident: B20
  doi: 10.7150/ijbs.70691
– ident: B6
  doi: 10.3390/ijms222011137
– ident: B15
  doi: 10.3389/fimmu.2024.1507283
– ident: B19
  doi: 10.1002/jcb.26174
– ident: B23
  doi: 10.1056/NEJMoa1500596
– ident: B10
  doi: 10.3389/fnut.2024.1515918
– ident: B2
  doi: 10.26574/maedica.2021.16.3.375
– ident: B24
  doi: 10.1056/NEJMoa2200075
– ident: B8
  doi: 10.1186/s12885-025-13816-7
– ident: B12
  doi: 10.3748/wjg.v31.i5.102249
– ident: B21
  doi: 10.3390/cancers17010154
– ident: B5
  doi: 10.5009/gnl17556
– ident: B22
  doi: 10.1136/jitc-2021-003091
SSID ssj0023352
Score 2.4531758
SecondaryResourceType review_article
Snippet Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages....
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 104794
SubjectTerms Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - blood
Blood Glucose - analysis
Humans
Immunotherapy - methods
Neoplasm Staging
Precision Medicine - methods
Prognosis
Progression-Free Survival
Stomach Neoplasms - blood
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - therapy
Treatment Outcome
Triglycerides - blood
Title Triglyceride-glucose index as a prognostic indicator in advanced gastric cancer: Insights and future research
URI https://www.ncbi.nlm.nih.gov/pubmed/40521254
https://www.proquest.com/docview/3219009255
https://pubmed.ncbi.nlm.nih.gov/PMC12159980
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkNBeEIiv8iUj8TalJLHzxRsgpjEBT5uo9hLZjt1kYsm0NiD4D_ivubOTNF2LBLxEqXM9q3e_nn3O-WdCXiouooJp4UkQ8HiiMi9Vhnu-YgAXIY2x7PyfPsdHp_x4Hs0nk1-jqqV2JWfq5859Jf_jVWgDv-Iu2X_w7KAUGuAe_AtX8DBc_87HkFp__aGgq0IPxeeW_xCPjxG2-KpukIkZW3F1zlafr1_8LwQe26Gw9Au04OrAh3qJ6bpjbnaEIwcdIVA5nsi6IpwR74RV1SDD55WjdUJtX46Ho7vOSuFWZUtdL7xDXQ2lQFWL7fNKNN7HfiDFYaJ1SAXpt4Pw3DaelRVo6ES7JYswsgWCbljVNrSFECc9GBj9cRzuRoMOb8koqgaWB39XwEfyHPDS9_PF7BsLZlWQzLaF4fdeXlgIcLtV2bFWX6PZ7h_dIDdDyDjCfuGny91xa5rbc4VdvtrucJ_c6lVsTnG28pbr5bej-czJHXK7S0ToG4equ2Si63vkYheiqEUUFUsq6BpRdEAU3NEeUbRDFHWIek17PFHAE3V4oj2e7pPTw_cn74687kAOT7EoXnlSMfgLJybjvCh8ropQ-0mcwERIwKckMUoaP82MSlkaFTzQMXyjYMLESWgCzdgDslc3tX5EqI4kR2o6ZdKEGwlZv2ImSOE2kkLKcEoOehvml453JYd8FY2fg_FzMH4Oxs-d8afkRW_mHMIjvvMStW7aZc4AacgrFkVT8tCZfdDX-2tK0g2HDAJIvb75pK5KS8GOnCxZlvqP_6j0CdlfQ_8p2VtdtfoZzF9X8rlF1m9Z26C7
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Triglyceride-glucose+index+as+a+prognostic+indicator+in+advanced+gastric+cancer%3A+Insights+and+future+research&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Zhao%2C+Cheng-Fei&rft.au=Liu%2C+Xiao-Ling&rft.au=Wu%2C+Ning-Bi&rft.au=Xu%2C+Zhi-Feng&rft.date=2025-05-07&rft.eissn=2219-2840&rft.volume=31&rft.issue=17&rft.spage=104794&rft_id=info:doi/10.3748%2Fwjg.v31.i17.104794&rft_id=info%3Apmid%2F40521254&rft.externalDocID=40521254
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1007-9327&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1007-9327&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1007-9327&client=summon